{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:31:44Z","timestamp":1790094704603,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Talent Development Program of Changzheng Hospital","award":["YQ722"],"award-info":[{"award-number":["YQ722"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Primary intraocular lymphoma (PIOL) is a rare malignancy with a poor prognosis, but its optimal therapy remains unclear. Herein, we aimed to analyze the epidemiology and survival outcomes of PIOL patients based on a population-based cancer registry in the United States.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients diagnosed with PIOL between 1992 and 2018 were identified from the Surveillance Epidemiology and End Results program. The patients were divided into two groups: those aged\u2009&lt;\u200960\u00a0years and\u2009\u2265\u200960\u00a0years. We used the chi-squared test to analyze the differences between the two groups. Descriptive analyses were performed to analyze epidemiological characteristics and treatment. The likely prognostic factors were analyzed by Kaplan\u2013Meier curves and Cox proportional hazards models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The overall incidence of PIOL was 0.23\/1,000,000, which was steadily increasing from 1992 to 2018, with an annual percentage change of 2.35. In total, 326 patients (mean age, 66.1\u00a0years) with PIOL were included in this study, 72.1% were aged\u2009\u2265\u200960\u00a0years, 84.4% were White, and 60.4% were female. The most common pathological type was diffuse large B-cell lymphoma (DLBCL), but in patients aged\u2009&lt;\u200960\u00a0years, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue was the most common. The disease-specific survival rates were 74.2% and 61.5% 5 and 10\u00a0years after diagnosis, respectively. Survival analysis found that surgery, radiation, and chemotherapy did not lead to better prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PIOL is a rare disease with poor prognosis, and its incidence has been increasing for nearly 30\u00a0years. It usually affects people aged\u2009\u2265\u200960\u00a0years, and DLBCL is the most common pathological type of PIOL. Patients aged\u2009&lt;\u200960\u00a0years and with non-DLBCL type have improved survival. Survival of PIOL has improved in recent years.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-022-02702-6","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T16:21:16Z","timestamp":1670948476000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Epidemiology and survival outcomes of patients with primary intraocular lymphoma: a population-based analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Lin-feng","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-di","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"issue":"3","key":"2702_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00001622-200105000-00001","volume":"13","author":"RR Buggage","year":"2001","unstructured":"Buggage RR, Chan CC, Nussenblatt RB. Ocular manifestations of central nervous system lymphoma. Curr Opin Oncol. 2001;13(3):137\u201342. https:\/\/doi.org\/10.1097\/00001622-200105000-00001.","journal-title":"Curr Opin Oncol"},{"issue":"8","key":"2702_CR2","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1043\/1543-2165-133.8.1228","volume":"133","author":"LJ Faia","year":"2009","unstructured":"Faia LJ, Chan CC. Primary intraocular lymphoma. Arch Pathol Lab Med. 2009;133(8):1228\u201332. https:\/\/doi.org\/10.1043\/1543-2165-133.8.1228.","journal-title":"Arch Pathol Lab Med"},{"key":"2702_CR3","doi-asserted-by":"publisher","first-page":"204062072110661","DOI":"10.1177\/20406207211066166","volume":"13","author":"C Lv","year":"2022","unstructured":"Lv C, et al. Primary central nervous system lymphoma in the United States, 1975\u20132017. Ther Adv Hematol. 2022;13:20406207211066170. https:\/\/doi.org\/10.1177\/20406207211066166.","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"2702_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/nox187","volume":"20","author":"JS Mendez","year":"2018","unstructured":"Mendez JS, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018;20(5):687\u201394. https:\/\/doi.org\/10.1093\/neuonc\/nox187.","journal-title":"Neuro Oncol"},{"issue":"11","key":"2702_CR5","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1634\/theoncologist.2011-0210","volume":"16","author":"CC Chan","year":"2011","unstructured":"Chan CC, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011;16(11):1589\u201399. https:\/\/doi.org\/10.1634\/theoncologist.2011-0210.","journal-title":"Oncologist"},{"issue":"4","key":"2702_CR6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00277-015-2582-x","volume":"95","author":"WL Ma","year":"2016","unstructured":"Ma WL, et al. Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection. Ann Hematol. 2016;95(4):593\u2013601. https:\/\/doi.org\/10.1007\/s00277-015-2582-x.","journal-title":"Ann Hematol"},{"issue":"5","key":"2702_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/107327480401100502","volume":"11","author":"CC Chan","year":"2004","unstructured":"Chan CC, Wallace DJ. Intraocular lymphoma: update on diagnosis and management. Cancer Control. 2004;11(5):285\u201395. https:\/\/doi.org\/10.1177\/107327480401100502.","journal-title":"Cancer Control"},{"issue":"9","key":"2702_CR8","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/sj.eye.6702437","volume":"21","author":"A Berenbom","year":"2007","unstructured":"Berenbom A, et al. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye (Lond). 2007;21(9):1198\u2013201. https:\/\/doi.org\/10.1038\/sj.eye.6702437.","journal-title":"Eye (Lond)"},{"issue":"4","key":"2702_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.hoc.2005.05.011","volume":"19","author":"GA Levy-Clarke","year":"2005","unstructured":"Levy-Clarke GA, Chan CC, Nussenblatt RB. Diagnosis and management of primary intraocular lymphoma. Hematol Oncol Clin North Am. 2005;19(4):739\u201349. https:\/\/doi.org\/10.1016\/j.hoc.2005.05.011 (viii).","journal-title":"Hematol Oncol Clin North Am"},{"key":"2702_CR10","doi-asserted-by":"publisher","first-page":"100761","DOI":"10.1016\/j.preteyeres.2019.05.002","volume":"72","author":"S Touhami","year":"2019","unstructured":"Touhami S, et al. Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis. Prog Retin Eye Res. 2019;72:100761. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.05.002.","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"2702_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/sj.eye.6700378","volume":"17","author":"PM Hoffman","year":"2003","unstructured":"Hoffman PM, et al. Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye (Lond). 2003;17(4):513\u201321. https:\/\/doi.org\/10.1038\/sj.eye.6700378.","journal-title":"Eye (Lond)"},{"issue":"6","key":"2702_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/s0039-6257(01)00217-x","volume":"45","author":"MK Gill","year":"2001","unstructured":"Gill MK, Jampol LM. Variations in the presentation of primary intraocular lymphoma: case reports and a review. Surv Ophthalmol. 2001;45(6):463\u201371. https:\/\/doi.org\/10.1016\/s0039-6257(01)00217-x.","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"2702_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/00006982-200202000-00007","volume":"22","author":"G Velez","year":"2002","unstructured":"Velez G, Chan CC, Csaky KG. Fluorescein angiographic findings in primary intraocular lymphoma. Retina. 2002;22(1):37\u201343. https:\/\/doi.org\/10.1097\/00006982-200202000-00007.","journal-title":"Retina"},{"issue":"3","key":"2702_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/09273948.2016.1193206","volume":"26","author":"K Abu Samra","year":"2018","unstructured":"Abu Samra K, et al. Intraocular Lymphoma: Descriptive Data of 26 Patients Including Clinico-pathologic Features, Vitreous Findings, and Treatment Outcomes. Ocul Immunol Inflamm. 2018;26(3):347\u201352. https:\/\/doi.org\/10.1080\/09273948.2016.1193206.","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"2702_CR15","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.18240\/ijo.2017.08.19","volume":"10","author":"LJ Tang","year":"2017","unstructured":"Tang LJ, Gu CL, Zhang P. Intraocular lymphoma. Int J Ophthalmol. 2017;10(8):1301\u20137. https:\/\/doi.org\/10.18240\/ijo.2017.08.19.","journal-title":"Int J Ophthalmol"},{"issue":"5","key":"2702_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.survophthal.2013.12.001","volume":"59","author":"MS Sagoo","year":"2014","unstructured":"Sagoo MS, et al. Primary intraocular lymphoma. Surv Ophthalmol. 2014;59(5):503\u201316. https:\/\/doi.org\/10.1016\/j.survophthal.2013.12.001.","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"2702_CR17","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1093\/annonc\/mdm340","volume":"18","author":"SA Grimm","year":"2007","unstructured":"Grimm SA, et al. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol. 2007;18(11):1851\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdm340.","journal-title":"Ann Oncol"},{"issue":"17","key":"2702_CR18","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1182\/blood.2020008235","volume":"138","author":"C Soussain","year":"2021","unstructured":"Soussain C, Malaise D, Cassoux N. Primary vitreoretinal lymphoma: a diagnostic and management challenge. Blood. 2021;138(17):1519\u201334. https:\/\/doi.org\/10.1182\/blood.2020008235.","journal-title":"Blood"},{"issue":"10","key":"2702_CR19","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s00417-003-0749-y","volume":"241","author":"SE Coupland","year":"2003","unstructured":"Coupland SE, et al. Evaluation of vitrectomy specimens and chorioretinal biopsies in the diagnosis of primary intraocular lymphoma in patients with Masquerade syndrome. Graefes Arch Clin Exp Ophthalmol. 2003;241(10):860\u201370. https:\/\/doi.org\/10.1007\/s00417-003-0749-y.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"2702_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10384-009-0662-y","volume":"53","author":"S Sugita","year":"2009","unstructured":"Sugita S, et al. Diagnosis of intraocular lymphoma by polymerase chain reaction analysis and cytokine profiling of the vitreous fluid. Jpn J Ophthalmol. 2009;53(3):209\u201314. https:\/\/doi.org\/10.1007\/s10384-009-0662-y.","journal-title":"Jpn J Ophthalmol"},{"issue":"7","key":"2702_CR21","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/S1470-2045(15)00076-5","volume":"16","author":"K Hoang-Xuan","year":"2015","unstructured":"Hoang-Xuan K, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16(7):e322-32. https:\/\/doi.org\/10.1016\/S1470-2045(15)00076-5.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2702_CR22","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/hon.2741","volume":"38","author":"M Xiao","year":"2020","unstructured":"Xiao M, et al. The incidence and survival outcomes of patients with primary cardiac lymphoma: A SEER-based analysis. Hematol Oncol. 2020;38(3):334\u201343. https:\/\/doi.org\/10.1002\/hon.2741.","journal-title":"Hematol Oncol"},{"key":"2702_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.breast.2019.11.008","volume":"49","author":"S Lin","year":"2020","unstructured":"Lin S, et al. Clinicopathological characteristics and survival outcomes in breast carcinosarcoma: A SEER population-based study. Breast. 2020;49:157\u201364. https:\/\/doi.org\/10.1016\/j.breast.2019.11.008.","journal-title":"Breast"},{"key":"2702_CR24","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 18 Registries, Nov 2020 Sub (2000\u20132018) - Linked To County Attributes - Total U.S., 1969\u20132019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission."},{"key":"2702_CR25","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 13 Registries, Nov 2020 Sub (1992\u20132018) - Linked To County Attributes - Total U.S., 1969\u20132019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission."},{"issue":"2","key":"2702_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/09273940902957305","volume":"17","author":"M Mochizuki","year":"2009","unstructured":"Mochizuki M, Singh AD. Epidemiology and clinical features of intraocular lymphoma. Ocul Immunol Inflamm. 2009;17(2):69\u201372. https:\/\/doi.org\/10.1080\/09273940902957305.","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"2702_CR27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11910-013-0344-5","volume":"13","author":"M Daras","year":"2013","unstructured":"Daras M, DeAngelis LM. Management of elderly patients with primary central nervous system lymphoma. Curr Neurol Neurosci Rep. 2013;13(5):344. https:\/\/doi.org\/10.1007\/s11910-013-0344-5.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"2702_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000495284","volume":"141","author":"T Siegal","year":"2019","unstructured":"Siegal T, Bairey O. Primary CNS Lymphoma in the Elderly: The Challenge. Acta Haematol. 2019;141(3):138\u201345. https:\/\/doi.org\/10.1159\/000495284.","journal-title":"Acta Haematol"},{"issue":"2","key":"2702_CR29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1365-2141.2004.05028.x","volume":"126","author":"A Hormigo","year":"2004","unstructured":"Hormigo A, et al. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol. 2004;126(2):202\u20138. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05028.x.","journal-title":"Br J Haematol"},{"issue":"4","key":"2702_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/17474086.2017.1305264","volume":"10","author":"A Chiappella","year":"2017","unstructured":"Chiappella A, et al. Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives. Expert Rev Hematol. 2017;10(4):289\u201397. https:\/\/doi.org\/10.1080\/17474086.2017.1305264.","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"2702_CR31","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s00417-004-1050-4","volume":"243","author":"SE Coupland","year":"2005","unstructured":"Coupland SE, et al. Diagnosis of a primary uveal extranodal marginal zone B-cell lymphoma by chorioretinal biopsy: case report. Graefes Arch Clin Exp Ophthalmol. 2005;243(5):482\u20136. https:\/\/doi.org\/10.1007\/s00417-004-1050-4.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"2702_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/s0161-6420(99)00025-1","volume":"107","author":"GC Cockerham","year":"2000","unstructured":"Cockerham GC, et al. Re-evaluation of \u201creactive lymphoid hyperplasia of the uvea\u201d: an immunohistochemical and molecular analysis of 10 cases. Ophthalmology. 2000;107(1):151\u20138. https:\/\/doi.org\/10.1016\/s0161-6420(99)00025-1.","journal-title":"Ophthalmology"},{"issue":"11","key":"2702_CR33","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00417-004-0973-0","volume":"242","author":"SE Coupland","year":"2004","unstructured":"Coupland SE, Heimann H, Bechrakis NE. Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol. 2004;242(11):901\u201313. https:\/\/doi.org\/10.1007\/s00417-004-0973-0.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"2702_CR34","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1442-9071.2008.01843.x","volume":"36","author":"SE Coupland","year":"2008","unstructured":"Coupland SE, Damato B. Understanding intraocular lymphomas. Clin Exp Ophthalmol. 2008;36(6):564\u201378. https:\/\/doi.org\/10.1111\/j.1442-9071.2008.01843.x.","journal-title":"Clin Exp Ophthalmol"},{"key":"2702_CR35","unstructured":"British Neuro-Oncology Society; National Cancer Action Team. Rare Brain and CNS Tumours Guidelines: Guidelines on the Diagnosis and Management of Adult Pineal Area Tumours. Published June 2011. http:\/\/www.bnos.org.uk\/wp-content\/uploads\/2015\/08\/Guidelines-on-the-Diagnosis-and-Management.pdf. Accessed 6 Apr 2016."},{"issue":"2","key":"2702_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/eye.2012.250","volume":"27","author":"JL Davis","year":"2013","unstructured":"Davis JL. Intraocular lymphoma: a clinical perspective. Eye (Lond). 2013;27(2):153\u201362. https:\/\/doi.org\/10.1038\/eye.2012.250.","journal-title":"Eye (Lond)"},{"issue":"9","key":"2702_CR37","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1080\/10428190600632881","volume":"47","author":"K Isobe","year":"2006","unstructured":"Isobe K, et al. Treatment of primary intraocular lymphoma with radiation therapy: a multi-institutional survey in Japan. Leuk Lymphoma. 2006;47(9):1800\u20135. https:\/\/doi.org\/10.1080\/10428190600632881.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2702_CR38","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/archopht.1997.01100160322009","volume":"115","author":"BC Fishburne","year":"1997","unstructured":"Fishburne BC, et al. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol. 1997;115(9):1152\u20136. https:\/\/doi.org\/10.1001\/archopht.1997.01100160322009.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"2702_CR39","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/bjo.2007.127928","volume":"92","author":"S Frenkel","year":"2008","unstructured":"Frenkel S, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92(3):383\u20138. https:\/\/doi.org\/10.1136\/bjo.2007.127928.","journal-title":"Br J Ophthalmol"},{"key":"2702_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40942-018-0120-4","volume":"4","author":"JS Pulido","year":"2018","unstructured":"Pulido JS, et al. The diagnosis and treatment of primary vitreoretinal lymphoma: a review. Int J Retina Vitreous. 2018;4:18. https:\/\/doi.org\/10.1186\/s40942-018-0120-4.","journal-title":"Int J Retina Vitreous"},{"issue":"11","key":"2702_CR41","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1136\/bjophthalmol-2017-311574","volume":"102","author":"A Klimova","year":"2018","unstructured":"Klimova A, et al. Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse. Br J Ophthalmol. 2018;102(11):1579\u201385. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311574.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"2702_CR42","doi-asserted-by":"publisher","first-page":"574","DOI":"10.18240\/ijo.2021.04.15","volume":"14","author":"Y Di","year":"2021","unstructured":"Di Y, et al. Clinical features and treatment outcomes of intraocular lymphoma: a single-center experience in China. Int J Ophthalmol. 2021;14(4):574\u201381. https:\/\/doi.org\/10.18240\/ijo.2021.04.15.","journal-title":"Int J Ophthalmol"},{"issue":"6","key":"2702_CR43","doi-asserted-by":"publisher","first-page":"e65627","DOI":"10.1371\/journal.pone.0065627","volume":"8","author":"H Raja","year":"2013","unstructured":"Raja H, et al. Effect of intravitreal methotrexate and rituximab on interleukin-10 levels in aqueous humor of treated eyes with vitreoretinal lymphoma. PLoS One. 2013;8(6):e65627. https:\/\/doi.org\/10.1371\/journal.pone.0065627.","journal-title":"PLoS One"},{"issue":"2","key":"2702_CR44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/IAE.0b013e318192f574","volume":"29","author":"S Itty","year":"2009","unstructured":"Itty S, Pulido JS. Rituximab for intraocular lymphoma. Retina. 2009;29(2):129\u201332. https:\/\/doi.org\/10.1097\/IAE.0b013e318192f574.","journal-title":"Retina"},{"issue":"1","key":"2702_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/bjophthalmol-2013-304043","volume":"98","author":"KL Larkin","year":"2014","unstructured":"Larkin KL, et al. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma. Br J Ophthalmol. 2014;98(1):99\u2013103. https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304043.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"2702_CR46","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1038\/s41433-021-01500-6","volume":"35","author":"E Hearne","year":"2021","unstructured":"Hearne E, Netzer OT, Lightman S. Learning points in intraocular lymphoma. Eye (Lond). 2021;35(7):1815\u20137. https:\/\/doi.org\/10.1038\/s41433-021-01500-6.","journal-title":"Eye (Lond)"},{"issue":"17","key":"2702_CR47","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1212\/01.wnl.0000327672.04729.8c","volume":"71","author":"SA Grimm","year":"2008","unstructured":"Grimm SA, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology. 2008;71(17):1355\u201360. https:\/\/doi.org\/10.1212\/01.wnl.0000327672.04729.8c.","journal-title":"Neurology"},{"key":"2702_CR48","doi-asserted-by":"publisher","first-page":"808511","DOI":"10.3389\/fonc.2022.808511","volume":"12","author":"XY Zhao","year":"2022","unstructured":"Zhao XY, et al. Clinical Features, Diagnosis, Management and Prognosis of Primary Intraocular Lymphoma. Front Oncol. 2022;12:808511. https:\/\/doi.org\/10.3389\/fonc.2022.808511.","journal-title":"Front Oncol"},{"issue":"3","key":"2702_CR49","first-page":"247","volume":"1","author":"K Jahnke","year":"2007","unstructured":"Jahnke K, et al. Diagnosis and management of primary intraocular lymphoma: an update. Clin Ophthalmol. 2007;1(3):247\u201358.","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"2702_CR50","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/ICU.0000000000000620","volume":"30","author":"JS Takhar","year":"2019","unstructured":"Takhar JS, Doan TA, Gonzales JA. Primary vitreoretinal lymphoma: empowering our clinical suspicion. Curr Opin Ophthalmol. 2019;30(6):491\u20139. https:\/\/doi.org\/10.1097\/ICU.0000000000000620.","journal-title":"Curr Opin Ophthalmol"},{"key":"2702_CR51","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ajo.2021.09.032","volume":"236","author":"MC Santos","year":"2022","unstructured":"Santos MC, et al. Vitreoretinal Lymphoma: Optimizing Diagnostic Yield and Accuracy. Am J Ophthalmol. 2022;236:120\u20139. https:\/\/doi.org\/10.1016\/j.ajo.2021.09.032.","journal-title":"Am J Ophthalmol"},{"issue":"20","key":"2702_CR52","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1182\/blood.2019003073","volume":"135","author":"M Baron","year":"2020","unstructured":"Baron M, et al. Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. Blood. 2020;135(20):1811\u20135. https:\/\/doi.org\/10.1182\/blood.2019003073.","journal-title":"Blood"},{"issue":"4","key":"2702_CR53","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"H Ghesquieres","year":"2019","unstructured":"Ghesquieres H, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u201cproof of concept\u201d phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)dagger. Ann Oncol. 2019;30(4):621\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz032.","journal-title":"Ann Oncol"},{"key":"2702_CR54","doi-asserted-by":"publisher","first-page":"103010","DOI":"10.1016\/j.critrevonc.2020.103010","volume":"152","author":"K Hou","year":"2020","unstructured":"Hou K, et al. Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis. Crit Rev Oncol Hematol. 2020;152:103010. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103010.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"13","key":"2702_CR55","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","volume":"2","author":"JL Rubenstein","year":"2018","unstructured":"Rubenstein JL, et al. Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018;2(13):1595\u2013607. https:\/\/doi.org\/10.1182\/bloodadvances.2017014845.","journal-title":"Blood Adv"},{"issue":"7","key":"2702_CR56","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamaophthalmol.2017.1810","volume":"135","author":"CL Shields","year":"2017","unstructured":"Shields CL, et al. Intravitreal Melphalan for Treatment of Primary Vitreoretinal Lymphoma: A New Indication for an Old Drug. JAMA Ophthalmol. 2017;135(7):815\u20138. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.1810.","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"2702_CR57","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaophthalmol.2017.3286","volume":"135","author":"AH Ahmed","year":"2017","unstructured":"Ahmed AH, Foster CS, Shields CL. Association of Disease Location and Treatment With Survival in Diffuse Large B-Cell Lymphoma of the Eye and Ocular Adnexal Region. JAMA Ophthalmol. 2017;135(10):1062\u20138. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.3286.","journal-title":"JAMA Ophthalmol"}],"updated-by":[{"DOI":"10.1186\/s12886-023-02781-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000}}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02702-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02702-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02702-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T15:09:18Z","timestamp":1720710558000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02702-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2702"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02702-6","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12886-023-02781-z","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"2 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12886-023-02781-z","URL":"https:\/\/doi.org\/10.1186\/s12886-023-02781-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was evaluated by the Ethics Committee of Changzheng Hospital and deemed not to require ethics approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"486"}}